By Counterforce Health Team in Kesimpta (ofatumumab) —

How to Get Kesimpta (Ofatumumab) Covered by Blue Cross Blue Shield in Virginia: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Kesimpta Covered by BCBS Virginia

Anthem Blue Cross Blue Shield Virginia classifies Kesimpta (ofatumumab) as a non-preferred specialty drug requiring prior authorization and step therapy. To get covered, you need: (1) documented relapsing MS diagnosis with recent activity, (2) failure of at least 2 preferred first-line DMTs, and (3) completed hepatitis B screening. Start today by calling BCBS member services at 1-800-552-8355 to verify your specialty pharmacy network and request PA forms. If denied, Virginia offers binding external review through the State Corporation Commission within 120 days of your final internal appeal.

Table of Contents

Plan Types & Coverage Implications

Anthem Blue Cross Blue Shield dominates Virginia's commercial insurance market with approximately 43% market share. Your specific plan type affects how Kesimpta coverage works:

Commercial Plans (Employer/Individual)

  • HMO plans may require neurologist referrals before PA submission
  • PPO plans allow direct specialist access but still require PA
  • All commercial plans follow Anthem's Clinical Criteria CC-0174 for MS DMTs

Medicare Advantage

  • May have different formulary tiers than commercial plans
  • Follow Medicare Part D appeal timelines (different from commercial)

Virginia State Employee Plans (COVA HealthAware)

  • Use Anthem formulary but may have plan-specific overlays
  • Check your member handbook for additional requirements

Kesimpta's Formulary Status

Coverage Detail Status What This Means
Formulary Tier Non-preferred specialty Higher cost-sharing than preferred DMTs
Prior Authorization Required Must be approved before dispensing
Step Therapy Required Must try preferred alternatives first
Specialty Pharmacy Mandatory Cannot fill at retail pharmacies
Quantity Limits Monthly supply Aligned with FDA dosing schedule

Kesimpta appears on Anthem's Exclusive Specialty Drug List, meaning it must be obtained through designated specialty pharmacies for coverage. You can verify your plan's specific tier placement using Anthem's drug lookup tool by selecting Virginia as your state.

Prior Authorization Requirements

Anthem approves Kesimpta requests when all criteria are met according to Clinical Criteria CC-0174:

Medical Necessity Criteria

  1. Diagnosis: Relapsing multiple sclerosis (CIS, RRMS, or active SPMS)
  2. Functional Status: Ability to ambulate without aid for at least 100 meters (EDSS 0-5.5)
  3. Disease Activity: At least 2 relapses within 2 years OR 1 relapse within 1 year OR ≥1 T1 gadolinium-enhancing lesion on recent MRI
  4. Safety Screening: Completed hepatitis B testing (HBsAg, anti-HBc, anti-HBs)

Required Documentation

  • Neurologist's letter confirming relapsing MS diagnosis
  • MRI reports showing lesion activity or clinical notes documenting relapses
  • Hepatitis B screening results
  • Documentation of prior DMT failures (see step therapy below)
Tip: The 100-meter ambulation requirement aligns with the baseline EDSS scores in Kesimpta's pivotal trials. If you use mobility aids occasionally but can walk 100 meters unassisted, you likely meet this criterion.

Step Therapy & Preferred Alternatives

Before approving Kesimpta, Anthem requires documented failure or intolerance to preferred first-line agents. The 2026 Essential Drug List indicates step therapy requirements, though specific sequences aren't detailed in the formulary.

Typical First-Line Requirements

Based on Anthem's clinical criteria and MS treatment guidelines:

  • Generic dimethyl fumarate (preferred alternative specifically mentioned)
  • Glatiramer acetate (Copaxone/generics)
  • Interferon beta products (Avonex, Betaseron, Rebif)

Documentation Needed

For each prior therapy, provide:

  • Drug name, dose, and duration of treatment
  • Reason for discontinuation (lack of efficacy, adverse effects, intolerance)
  • Clinical evidence of failure (new relapses, MRI progression, side effects)
  • Dates of treatment periods
Note: "Failure" typically means 3-6 months of treatment without adequate response or development of intolerable side effects. Document specific symptoms or MRI changes that occurred during treatment.

Specialty Pharmacy Network

Kesimpta cannot be filled at retail pharmacies due to cold-chain storage requirements and patient support needs. Anthem's Virginia specialty pharmacy network includes:

In-Network Options

  • CVS Specialty (designated for medical benefit coverage)
  • BioPlus Specialty Pharmacy
  • CenterWell Pharmacy
  • Inova Retail and Specialty Pharmacy
  • MedStar Specialty Pharmacy
  • St. Matthews Specialty Pharmacy

Enrollment Process

  1. Your neurologist sends the prescription to an in-network specialty pharmacy
  2. The pharmacy contacts you to verify insurance and shipping details
  3. Medication ships directly to your home with temperature monitoring
  4. Pharmacy provides injection training and ongoing support

Call 1-800-552-8355 to confirm which specialty pharmacies are in-network for your specific plan, as networks can vary.

Cost-Share Basics

As a non-preferred specialty drug, Kesimpta typically falls into Tier 4 or 5 with higher cost-sharing:

  • Tier 4: Usually 30-40% coinsurance after deductible
  • Tier 5: Often 40-50% coinsurance after deductible
  • Deductible: May apply before coinsurance kicks in

Cost Support Options

  • Kesimpta Bridge Program: Covers gaps during PA/appeals for commercially insured patients with denials (call 1-855-828-1909)
  • Novartis Patient Assistance: Income-based programs for eligible patients
  • State pharmaceutical assistance: Virginia residents may qualify for additional programs

Contact your member services to understand your exact cost-sharing before starting treatment.

Submission Process

For Healthcare Providers

Submit PA requests through:

  • Anthem Provider Portal (providernews.anthem.com)
  • Availity platform for electronic submissions
  • Fax: Use provider-specific fax numbers (verify current number)

Timeline Expectations

  • Standard PA: 14-30 days for determination
  • Urgent requests: 72 hours (requires clinical justification)
  • Incomplete submissions: May receive requests for additional information

Key Submission Elements

Strong PA submissions include:

  • Complete Clinical Criteria CC-0174 documentation
  • Detailed medical necessity letter addressing each criterion
  • Supporting clinical notes and imaging reports
  • Prior authorization history for previous DMTs

Common Approval Patterns

Based on Anthem's published criteria, successful Kesimpta approvals typically demonstrate:

Strong Clinical Narrative

  • Clear relapsing MS phenotype with recent activity
  • Documented functional impact of current disease activity
  • Specific reasons why preferred alternatives are unsuitable
  • Comprehensive safety assessment including HBV screening

Robust Prior Treatment History

  • At least 2 adequate trials of preferred DMTs
  • Clear documentation of treatment failures
  • Objective measures of disease progression during prior treatments
  • Contraindications or intolerances to remaining preferred options

Complete Safety Documentation

  • Hepatitis B surface antigen (HBsAg): negative
  • Hepatitis B core antibody (anti-HBc): document status
  • Hepatitis B surface antibody (anti-HBs): document status
  • Plan for ongoing monitoring during treatment

Appeals Playbook for Virginia

If your initial PA is denied, Virginia provides a structured appeals process with specific timelines and requirements.

Internal Appeals Process

Appeal Level Timeline Requirements Contact Method
First Internal Appeal File within 180 days of denial Denial letter, enhanced medical records, specialist letter BCBS member services: 1-800-552-8355
Second Internal Appeal 15-30 days after first level Additional clinical evidence, peer review request Provider portal or member services
Expedited Appeal 72 hours for urgent cases Clinical urgency documentation Call member services immediately

External Review Process

After exhausting internal appeals, Virginia residents can request binding external review through the State Corporation Commission Bureau of Insurance.

Key Requirements:

  • File within 120 days of final internal denial
  • Use Form 216-A (External Review Request)
  • Include all denial letters and supporting medical records
  • Decision is binding on the insurance company

Contact Information: Virginia SCC Bureau of Insurance

From our advocates: We've seen many Virginia patients succeed with external review when their neurologist provides a comprehensive letter explaining why Kesimpta is medically necessary and why preferred alternatives aren't suitable. The independent medical reviewers often have different perspectives than the insurance company's initial reviewers, especially for complex MS cases.

When to Contact Virginia Regulators

Contact the Virginia State Corporation Commission if you experience:

  • Delays beyond required timelines
  • Requests for inappropriate documentation
  • Denial of expedited appeals for urgent situations
  • Procedural violations during the appeals process

The Office of the Managed Care Ombudsman can also assist with understanding appeal rights and sometimes resolve issues informally. Reach them at 1-877-310-6560.

For patients navigating complex insurance denials, Counterforce Health provides specialized support in turning insurance denials into targeted, evidence-backed appeals. Their platform helps identify denial reasons and drafts point-by-point rebuttals aligned to your plan's specific policies.

FAQ

How long does BCBS Virginia PA take? Standard prior authorizations take 14-30 days. Urgent requests are decided within 72 hours if clinical urgency is documented.

What if Kesimpta is non-formulary on my plan? Request a formulary exception with documentation that preferred alternatives are unsuitable due to contraindications, previous failures, or intolerances.

Can I request expedited appeal? Yes, if your neurologist certifies that waiting could seriously jeopardize your health. Virginia provides expedited external review within 72 hours for urgent cases.

Does step therapy apply if I failed DMTs outside Virginia? Yes, documented treatment failures from other states count toward step therapy requirements. Provide complete records from previous providers.

What happens if external review upholds the denial? The decision is final and binding. You may consider other options like employer appeals (for self-funded plans) or legal consultation if you suspect policy violations.

How much will Kesimpta cost with BCBS Virginia? Costs vary by plan, but expect 30-50% coinsurance for specialty tiers. Contact member services for your specific cost-sharing and check manufacturer support programs.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance policies and state regulations change frequently. Always verify current requirements with your insurance company and consult healthcare professionals for medical decisions. For personalized assistance with insurance appeals, consider consulting with Counterforce Health or other qualified advocacy services.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.